source
- Cullinan-Taiho eye FDA filing for zipalertinib after trial shows strong PFS benefit despite three deathsCullinan Therapeutics and its partner Taiho Oncology said they will seek FDA approval for zipalertinib, an oral therapy for a subset of non‑small cell lung cancer, based on data from a late‑stage s…
- Blood centers poised to boost cell and gene therapy supply chainsBlood centers have the donors, resources and community footprint that drug sponsors need to address supply chain bottlenecks for cell and gene therapies. Cell and gene therapies such as CAR‑T and…